Department of Family Medicine, College of Medicine, Busan Paik Hospital, Inje University, Busan, Korea.
Eur J Cancer Care (Engl). 2021 Mar;30(2):e13365. doi: 10.1111/ecc.13365. Epub 2020 Nov 11.
To evaluate the associations of combinations of sarcopenia and adiposity phenotypes with 10-year cardiovascular disease (CVD) risk scores in cancer survivors and non-cancer participants.
In 19,019 individuals including 1023 cancer survivors free of CVD who were aged ≥30 years from the Korea National Health and Nutrition Examination Survey, combination groups of sarcopenia, obesity and abdominal obesity based on handgrip strength, BMI and waist circumference, respectively, were generated and 10-year CVD risk scores based on Framingham risk model were determined.
After adjusting for socio-demographic factors, health behaviours, dietary intake of nutrients and time since cancer diagnosis and current cancer therapy (in cancer survivors), cancer survivors with sarcopenic non-obesity, non-sarcopenic abdominal obesity or sarcopenic abdominal obesity had, respectively, 84%, 85% and 3.61-fold higher odds for ≥10% CVD risk scores compared with cancer survivors without those phenotypes. In non-cancer participants, sarcopenia, obesity, abdominal obesity and combinations of those phenotypes had higher odds from 1.37 (in those with obesity) to 4.24 (in those with sarcopenic abdominal obesity) for ≥10% CVD risk scores compared with reference phenotypes. In conclusion, cancer survivors and non-cancer participants with sarcopenia, obesity, abdominal obesity or combination of those phenotypes had increased 10-year CVD risk scores.
评估肌少症和肥胖表型组合与癌症幸存者和非癌症参与者 10 年心血管疾病 (CVD) 风险评分的相关性。
在韩国国家健康和营养检查调查中，纳入了 19019 名年龄≥30 岁且无 CVD 的癌症幸存者（1023 名），根据握力、BMI 和腰围分别生成了肌少症、肥胖和腹型肥胖的组合组，并根据弗雷明汉风险模型确定了 10 年 CVD 风险评分。
在调整了社会人口因素、健康行为、营养素的饮食摄入以及癌症诊断和当前癌症治疗后的时间（在癌症幸存者中）后，与无这些表型的癌症幸存者相比，具有非肌少症性肥胖、非肌少症性腹型肥胖或肌少症性腹型肥胖的癌症幸存者具有分别为 84%、85%和 3.61 倍的更高可能性出现≥10%的 CVD 风险评分。在非癌症参与者中，与参考表型相比，肌少症、肥胖、腹型肥胖以及这些表型的组合具有更高的可能性，从 1.37（肥胖者）到 4.24（肌少症性腹型肥胖者）出现≥10%的 CVD 风险评分。总之，具有肌少症、肥胖、腹型肥胖或这些表型组合的癌症幸存者和非癌症参与者的 10 年 CVD 风险评分增加。
